GLP-1 receptor
Assets acting on this target.
- Class
- GLP-1 receptor agonist
The glucagon-like peptide-1 (GLP-1) receptor is a G protein-coupled receptor expressed on pancreatic beta cells, in the central nervous system, and in the gastrointestinal tract. Its natural ligand, GLP-1, is an incretin hormone released from the gut after eating, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on appetite-regulating centers in the brain to promote satiety. Because native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4, therapeutic strategies use synthetic peptides, engineered proteins, or small molecules that activate the receptor with greater metabolic stability and prolonged duration of action. Agonism of this receptor addresses two intertwined disease processes: impaired glucose regulation in type 2 diabetes and excess body weight, since the same receptor pathway that improves insulin release and lowers blood glucose also reduces caloric intake. The breadth of chemical modalities pursued for this target, spanning injectable peptides, longer-acting fusion proteins, and increasingly oral small molecules, reflects efforts to improve convenience, dosing frequency, and manufacturing while achieving comparable receptor activation. Combination approaches pairing GLP-1 agonism with other hormonal pathways aim to extend metabolic benefit beyond what receptor activation alone provides.
By indication
Related mechanisms
GLP-1 receptor drugs compared
51 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| dulaglutideTrulicity | Eli Lilly | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes |
| Liraglutide (Saxenda)Saxenda | Novo Nordisk | peptide | Approved | Approved in Obesity |
| Liraglutide (Victoza)Victoza | Novo Nordisk | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes |
| lixisenatideAdlyxin / Lyxumia | Sanofi, Zealand Pharma | peptide | Approved | Approved in Type 2 Diabetes |
| orforglipronFoundayo | Chugai Pharma, Eli Lilly | small molecule | Approved | Approved in Obesity; Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Hypertension; Phase 3 in Osteoarthritis; Phase 3 in Type 2 Diabetes |
| Semaglutide (Ozempic)Ozempic | Novo Nordisk | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Chronic Kidney Disease; Approved in Type 2 Diabetes |
| Semaglutide (Rybelsus)Rybelsus | Novo Nordisk | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Type 2 Diabetes |
| Semaglutide (Wegovy tablets)Wegovy | Novo Nordisk | peptide | Approved | Approved in Obesity |
| Semaglutide (Wegovy)Wegovy | Novo Nordisk | peptide | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in MASH / NASH; Approved in Obesity; Phase 3 in Heart Failure with Preserved Ejection Fraction |
| Albenatide | ConjuChem, Hebei Changshan Biochemical Pharmaceutical Co., Ltd | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| aleniglipron | Structure Therapeutics | small molecule | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| ASC30 | Ascletis Pharma | small molecule | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| Berobenatide | Pfizer | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| Bofanglutide | A. Menarini, Gan & Lee Pharmaceuticals, JW Pharmaceutical, Lupin Limited | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| cagrilintide/semaglutideCagriSema | Novo Nordisk | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| DA-302168S | Chendu DIAO Pharmaceutical Group | small molecule | Phase 3 | Phase 3 in Obesity; Phase 2 in Type 2 Diabetes |
| ecnoglutide | Pfizer, Sciwind Biosciences | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Osteoarthritis; Phase 3 in Type 2 Diabetes |
| Efmedaglutide alfaShanmeining | CSPC Pharmaceutical Group, TJ Biopharma Co., Ltd. | fusion protein | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| efpeglenatide | Hanmi Pharmaceutical, Laboratorios Sanfer | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| efsubaglutide alfa | Shanghai Yinnuo Pharmaceutical Technology | protein (Fc-fusion) | Phase 3 | Phase 3 in Type 2 Diabetes; Phase 2/3 in Obesity |
| elecoglipron | AstraZeneca, Eccogene | small molecule | Phase 3 | Phase 3 in Chronic Kidney Disease; Phase 3 in Heart Failure; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| enicepatide | Chugai Pharma, Roche | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| exendin-4 Fc fusion (JY09) | Beijing Dongfang Biotech | protein | Phase 3 | Phase 3 in Type 2 Diabetes |
| HDG1901 | Hangzhou Zhongmei Huadong Pharmaceutical | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical | small molecule | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| IcoSemaKyinsu | Novo Nordisk | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| MDR-001 | MindRank AI | small molecule | Phase 3 | Phase 3 in Obesity |
| Noiiglutide | Jiangsu Hengrui Pharmaceuticals | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| Pegloxenatide (Fulaimei)Fulaimei | Hansoh Pharmaceutical Group | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| Safiglipron (HRS-7535) | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | small molecule | Phase 3 | Phase 3 in Chronic Kidney Disease; Phase 3 in Hypertension; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Heart Failure |
| VCT220 | Ji Xing Pharmaceuticals (CORXEL), Vincentage Pharma | small molecule | Phase 3 | Phase 3 in Obesity; Phase 2 in Hypertension; Phase 2 in Type 2 Diabetes |
| Visepegenatide (PB-119) | PegBio | peptide | Phase 3 | Phase 3 in Type 2 Diabetes |
| zovaglutide | Beijing QL Biopharmaceutical | peptide | Phase 3 | Phase 3 in Obesity |
| Ecnoglutide (VRB-101) | Sciwind Biosciences, Verdiva Bio | peptide | Phase 2 | Phase 2 in Obesity |
| Exenatide (PT320) | Peptron | peptide | Phase 2 | Phase 2 in Parkinson's Disease |
| regor GLP-1 | Regor Pharmaceuticals | small molecule | Phase 2 | Phase 2 in Obesity; Phase 2 in Type 2 Diabetes |
| SAL0150 | Shenzhen Salubris Pharmaceuticals | small molecule | Phase 2 | Phase 2 in Type 2 Diabetes |
| TE-8105 | Immunwork | peptide | Phase 2 | Phase 2 in Obesity |
| Tifeglipron | Roche | small molecule | Phase 2 | Phase 2 in Obesity; Phase 2 in Type 2 Diabetes |
| TTP273 | vTv Therapeutics | small molecule | Phase 2 | Phase 2 in Type 2 Diabetes |
Showing the 40 furthest-developed of 51 drugs. The roster below lists them all, with filters.